Recombinant Human Relaxin receptor 1 (RXFP1)

What is RXFP1 and where is it expressed in human tissues?

RXFP1 is the main receptor for the peptide hormone relaxin and is expressed across multiple tissues in the human body. It is found in the heart, kidney, lung, skin, liver, blood vessels, and brain . This broad expression pattern explains the diverse physiological effects observed upon receptor activation. The receptor is a G protein-coupled receptor (GPCR) with unique structural characteristics, including a large ectodomain with 10 leucine-rich repeats (LRRs) . Expression studies using various techniques including RT-PCR and receptor autoradiography have provided detailed maps of RXFP1 distribution, though researchers should be cautious about interpretations from RT-PCR data alone as they may not always reflect physiologically relevant expression levels .

What is the primary signaling pathway activated by RXFP1?

RXFP1 primarily functions as a Gs protein-coupled receptor that stimulates adenylyl cyclase, resulting in increased intracellular cyclic adenosine monophosphate (cAMP) concentrations . This represents the most robust and well-characterized response to relaxin binding. For experimental assessment of RXFP1 activation, cAMP accumulation assays in various cell types are commonly employed, including OVCAR5 cells with endogenous RXFP1 expression or HEK293 cells with transiently expressed RXFP1 . When designing experiments to measure RXFP1 activity, researchers should note that basal cAMP levels can be heterogeneous across cell passages, necessitating appropriate normalization approaches (such as expressing results as a percentage of response to a standard concentration of relaxin) .

What physiological roles does RXFP1 play in normal human biology?

RXFP1 signaling regulates multiple physiological processes in both males and females. The receptor plays critical roles in:

• Pregnancy and reproduction, where it contributes to myometrial quiescence and softening

• The hypertrophy of the cervix during pregnancy

• Development of mammary glands and papilla

• Cardiovascular function including hemodynamic regulation

• Tissue remodeling and anti-fibrotic processes

RXFP1 also modulates the physiology of numerous organs including the heart, lungs, liver, and other systems . When investigating RXFP1 biology, researchers should consider sex-specific differences in receptor expression and function, as these can significantly impact experimental outcomes.

How does RXFP1 engage multiple signaling pathways beyond cAMP?

While cAMP is the primary second messenger for RXFP1, the receptor activates multiple signaling pathways through complex coupling mechanisms. RXFP1 initially couples to Gs, but over time recruits coupling to G(alpha)(i3), causing additional cAMP accumulation via a G(alpha)(i3)-G beta gamma-phosphoinositide 3-kinase (PI3K)-protein kinase C (PKC) zeta pathway . Additionally, RXFP1 can activate Gi in vascular cells .

When studying RXFP1 signaling, researchers should account for:

• Cell type-specific differences in signaling outcomes

• Temporal dynamics of pathway activation

• Potential biased signaling by different ligands

Beyond G-protein signaling, RXFP1 activation leads to stimulation of various MAP kinases including MEK, ERK1/2, Akt and p38, depending on the cell type . In vascular tissues, relaxin-2 produces endothelium- and nitric oxide (NO)-dependent relaxation of arteries through RXFP1 activation coupled to Gi2-PI3K pathways .

What is the mechanism of RXFP1 activation by relaxin binding?

Unlike typical glycoprotein hormone receptors that signal through a steric "push-pull" mechanism, RXFP1 activation involves a distinct process due to the small size (6 kDa) of the relaxin-2 peptide . Binding occurs through a two-step process:

• High-affinity binding to the extracellular domain of RXFP1

• Engagement with an additional binding site in the transmembrane (TM) exoloops

Structural analysis has revealed that once the B-chains of relaxin bind to the primary site in the leucine-rich repeats domain, the A-chain is presented in an orientation favorable for interaction with the TM exoloops . Critical residues involved in the activation mechanism include Leu402, Leu403, Phe564, and Leu566 in the hinge region and ECL2, which play essential roles in stabilizing the active conformation . Mutation studies have demonstrated that Leu402 and Leu403 are particularly crucial, as their substitution with alanine can completely abolish RXFP1 signaling .

How do cell and tissue-specific factors influence RXFP1 signaling outcomes?

RXFP1 signaling demonstrates remarkable tissue and cell-type specificity, which presents a significant challenge for translational research. In vascular cells, relaxin activates endothelial nitric oxide synthase (eNOS), while in other tissues it may stimulate neuronal NOS (nNOS) or induce expression of inducible NOS (iNOS) .

The downstream effects of RXFP1 activation are highly context-dependent:

In rat isolated lungs, the relaxin-mediated iNOS upregulation depends on a delicate balance between stimulatory ERK1/2 activation and counter-regulatory PI3K stimulation . This complex interplay highlights why researchers must carefully select appropriate cell models that recapitulate the relevant signaling environment when studying RXFP1.

What are the most reliable assays for measuring RXFP1 activation?

Several methodological approaches can be employed to assess RXFP1 activation, each with specific advantages and limitations:

• cAMP accumulation assays: The most commonly used readout for RXFP1 activation. OVCAR5 cells with endogenous RXFP1 expression or cell lines transiently expressing RXFP1 (HEK293-RXFP1, EA.hy926-RXFP1) are frequently utilized . For consistent potency (EC50) determinations across experiments, responses should be normalized to a positive control (typically 100 nM relaxin) due to heterogeneity in basal cAMP levels between cell passages .

• Binding assays: Competition binding assays using labeled relaxin can determine binding affinity. HEK293 cells expressing human RXFP1 are commonly used for such studies .

• Physiological readouts: In rodent models, chronotropic effects (increased heart rate) following RXFP1 activation provide a functional readout, though these effects are not translatable to humans . When using such models, researchers should be aware that higher doses of some RXFP1 agonists (like SA10SC-RLX) may be required compared to relaxin due to albumin binding affecting the free fraction available .

• Cell-specific functional assays: For liver fibrosis research, expression of fibrotic markers in hepatic stellate cells (e.g., LX-2 cell line) provides disease-relevant readouts .

When selecting an assay system, researchers should consider that RXFP1 signaling is cell type-specific, and differences in activity between cAMP activation and phenotypic outcomes (like changes in fibrotic markers) may exist .

How can I establish appropriate RXFP1 expression systems for pharmacological studies?

Establishing reliable expression systems for RXFP1 requires careful consideration of several factors:

• Expression level control: Physiological versus overexpression can significantly impact signaling outcomes. For comparative studies of mutants with lower expression, wild-type receptor expression might need to be reduced to enable fair comparisons .

• Cell background selection: Different cell lines provide distinct signaling environments. Options include:

  • HEK293 cells for transient expression and basic signaling studies

  • OVCAR5 cells with endogenous RXFP1 expression

  • EA.hy926_RXFP1 cells for vascular biology studies

  • LX-2 human hepatic stellate cells for liver fibrosis research

• Verification approaches:

  • Western blotting to confirm expression levels

  • Functional assays (cAMP accumulation) to verify receptor activity

  • Binding studies with labeled relaxin to confirm receptor presence at the cell surface

For mutation studies, researchers should verify that altered signaling is not simply due to reduced expression. When the L402A/L403A double mutant abolished RXFP1 signaling, expression was confirmed to be maintained at approximately 50% of wild-type levels, indicating a true functional deficit rather than an expression artifact .

What animal models are most appropriate for studying RXFP1 function in vivo?

While multiple animal models can be used to study RXFP1 biology, important species differences must be considered:

• Rodent models: Common but with important limitations

  • Rats: Show chronotropic responses to RXFP1 activation not observed in humans

  • Mice: Used for pressure overload models of cardiac dysfunction where AAV9-mediated RXFP1 expression shows therapeutic potential

  • Species differences: Human relaxin-2 is the counterpart of mouse relaxin-1, and mouse RXFP1 shows 89% identity to human RXFP1

• Transgenic approaches:

  • RXFP1 knockout models to assess receptor necessity

  • Tissue-specific RXFP1 expression (e.g., cardiac-specific expression using AAV9 vectors)

  • Reporter systems to track activation in specific tissues

When designing in vivo experiments, researchers should note that binding of relaxin to RXFP1 involves both common mechanisms across species and potential species-dependent differences in the interaction between relaxins, extracellular RXFP1 domains, and transmembrane exoloops . Additionally, pharmacokinetic considerations are important - SA10SC-RLX shows a longer half-life than relaxin due to albumin binding of its fatty acid chain, but this high albumin binding reduces its free fraction, requiring higher doses in vivo .

What is the evidence for RXFP1 as a therapeutic target in fibrotic diseases?

RXFP1 activation has demonstrated significant anti-fibrotic potential across multiple organ systems, supported by both preclinical and clinical evidence:

• Liver fibrosis: Upregulation of RXFP1 expression has been observed in human fibrotic liver tissues, suggesting pathophysiological relevance. Studies in the human hepatic stellate cell line LX-2 have shown that RXFP1 activation can modulate expression of fibrotic markers .

• Cardiac fibrosis: In models of pressure overload-induced cardiac dysfunction, AAV9-mediated RXFP1 expression showed therapeutic effects .

• Clinical investigations: Hemodynamic effects of relaxin have been recapitulated in healthy volunteers and patients with chronic heart failure. A 2-day infusion of relaxin improved renal and cardiac function, reducing pulmonary congestion and mortality at 6 months in patients with acute heart failure .

How does RXFP1 signaling influence cardiovascular pathophysiology?

RXFP1 signaling exerts multiple beneficial effects on cardiovascular physiology and pathophysiology:

• Hemodynamic effects: Relaxin produces vasodilation through endothelium- and NO-dependent relaxation of arteries via activation of RXFP1 coupled to Gi2-PI3K-Akt-eNOS pathways . This contributes to improved organ perfusion.

• Heart failure: In models of decompensated heart failure, RXFP1 activation has demonstrated cardioprotective effects and positive inotropic actions. RXFP1 is predominantly expressed in atrial cardiomyocytes under normal conditions, but ectopic ventricular expression via AAV9 delivery showed therapeutic effects in pressure overload models .

• Vascular remodeling: RXFP1 activation has been implicated in vascular remodeling processes, including effects on matrix metalloproteinases. Relaxin induces MMP-9 and MMP-13 via RXFP1, involving multiple pathways including PI3K, ERK, Akt and PKC-ζ .

• Primary varicosis: A novel role for relaxin-2 has been identified in the pathogenesis of primary varicosis, suggesting RXFP1 signaling may influence venous pathology .

The cardioprotective mechanisms of RXFP1 activation appear to involve both direct effects on cardiomyocytes and indirect effects through vascular actions, highlighting the complexity of RXFP1 biology in cardiovascular disease.

What are the challenges in developing RXFP1-targeted therapeutics?

Development of RXFP1-targeted therapeutics faces several significant challenges:

• Short half-life of peptide ligands: Human relaxin-2 (H2-RLX) has emerged as a potential therapy for cardiovascular and fibrotic diseases, but its short in vivo half-life presents an obstacle to long-term administration .

• Low druggability: High-throughput screening efforts have failed to identify many specific agonists or positive allosteric modulators beyond ML290, suggesting RXFP1 has relatively low druggability for small molecule approaches .

• Complex signaling biology: Differences in activity of compounds on cAMP activation compared with changes in expression of fibrotic markers indicate the need to better understand cell- and tissue-specific signaling mechanisms . This complexity makes target engagement and efficacy measurements challenging.

• Delivery challenges: For gene therapy approaches using AAV9-RXFP1, ensuring appropriate tissue targeting and expression levels presents additional hurdles .

• Translational gaps: Despite promising preclinical findings, there remain significant gaps in understanding how RXFP1 biology translates between animal models and humans. For example, chronotropic effects following RXFP1 activation observed in rodents are not translatable to humans .

Overcoming these challenges requires deeper understanding of tissue/cell-specific differences in RXFP1 expression, signaling pathways, and regulation of dependent genes in health and disease .

What are the key differences between peptide and small molecule RXFP1 agonists?

RXFP1 can be activated by both peptide ligands and small molecule agonists, each with distinct properties:

SA10SC-RLX represents an advancement in peptide design, showing a longer half-life and persistent activity compared to native relaxin. In rat models, SA10SC-RLX's effect on heart rate persisted for 15 hours versus only 4-6 hours for relaxin . This improved pharmacokinetic profile is attributed to binding of SA10SC-RLX's fatty acid chain to albumin, though this high albumin binding also reduces the free fraction available for receptor activation .

How can I characterize novel RXFP1 agonists or modulators?

Comprehensive characterization of novel RXFP1 ligands requires a multi-faceted approach:

• Binding characterization:

  • Competition binding assays against labeled relaxin in HEK293 cells expressing human RXFP1

  • Saturation binding studies to determine affinity constants

  • Binding kinetics to assess association and dissociation rates

• Functional assessment:

  • cAMP accumulation assays in multiple cell types (e.g., OVCAR5, EA.hy926_RXFP1)

  • Activation EC50 determination, normalized to relaxin response

  • Assessment in cell lines expressing various species orthologs (human, rat, mouse RXFP1)

• Signaling pathway profiling:

  • Beyond cAMP, evaluate activation of other pathways (ERK1/2, Akt, p38, NO production)

  • Biased signaling assessment comparing pathway activation patterns to relaxin

  • Cell type-specific signaling outcomes in disease-relevant cell models

• In vivo pharmacology:

  • Pharmacokinetic studies to determine half-life and distribution

  • In rats, chronotropic effects provide a functional readout

  • Efficacy in disease models (fibrosis, heart failure, etc.)

When comparing novel compounds to relaxin, researchers should consider using relaxin as a positive control within each experiment to account for inter-assay variability. For example, when characterizing SA10SC-RLX, data were expressed as a percentage of the 100 nM relaxin response for each experiment due to heterogeneous basal cAMP levels between cell passages .

What approaches can overcome the challenges in developing small molecule RXFP1 modulators?

Despite the low druggability of RXFP1, several strategic approaches may enhance the discovery of effective small molecule modulators:

• Structure-based design: Leveraging structural insights from cryo-EM studies of the RXFP1-relaxin-Gs complex to identify potential binding pockets and design targeted compounds .

• Focus on allosteric sites: The allosteric agonist ML290 demonstrates that alternative binding sites exist. Expanding efforts to identify and target novel allosteric pockets may yield compounds with distinct pharmacological profiles .

• Biased ligand development: Designing compounds that selectively activate beneficial signaling pathways while avoiding unwanted effects. The observation that ML290 stimulates many relaxin-activated pathways without ERK1/2 activation suggests pathway selectivity is achievable .

• Modified peptide approaches: SA10SC-RLX and other single-chain relaxin peptide mimetics (compounds 54, 59, and 64) demonstrate that structural modifications to peptide ligands can improve pharmacokinetic properties while maintaining receptor activity .

• Cell-specific screening cascades: Developing optimized screening approaches using therapeutically relevant cells that express physiological densities of RXFP1, rather than overexpression systems .

• Improved understanding of disease-relevant signaling: Better characterization of the specific RXFP1-mediated pathways that drive therapeutic benefits in different disease contexts will enable more focused screening strategies .

The discovery of novel ML290 analogues has provided valuable tools for understanding cell- and tissue-specific signaling mechanisms, even if these compounds have not yet advanced to clinical development .